OncoCyte Corporation (OCX)
OncoCyte Statistics
Share Statistics
OncoCyte has 21.06M shares outstanding. The number of shares has increased by 103.8% in one year.
| Shares Outstanding | 21.06M |
| Shares Change (YoY) | 103.8% |
| Shares Change (QoQ) | 25.88% |
| Owned by Institutions (%) | 0.43% |
| Shares Floating | 14.77M |
| Failed to Deliver (FTD) Shares | 150 |
| FTD / Avg. Volume | 0.17% |
Short Selling Information
The latest short interest is 319.4K, so 1.9% of the outstanding shares have been sold short.
| Short Interest | 319.4K |
| Short % of Shares Out | 1.9% |
| Short % of Float | 2.42% |
| Short Ratio (days to cover) | 4.68 |
Valuation Ratios
The PE ratio is -0.69 and the forward PE ratio is -1.17. OncoCyte's PEG ratio is 0.01.
| PE Ratio | -0.69 |
| Forward PE | -1.17 |
| PS Ratio | 12.73 |
| Forward PS | 10.2 |
| PB Ratio | 0.75 |
| P/FCF Ratio | -0.81 |
| PEG Ratio | 0.01 |
Enterprise Valuation
OncoCyte Corporation has an Enterprise Value (EV) of 18.69M.
| EV / Earnings | -0.67 |
| EV / Sales | 12.43 |
| EV / EBITDA | -0.81 |
| EV / EBIT | -0.74 |
| EV / FCF | -0.79 |
Financial Position
The company has a current ratio of 1.49, with a Debt / Equity ratio of 0.11.
| Current Ratio | 1.49 |
| Quick Ratio | 1.49 |
| Debt / Equity | 0.11 |
| Total Debt / Capitalization | 10.08 |
| Cash Flow / Debt | -8.13 |
| Interest Coverage | -483.38 |
Financial Efficiency
Return on equity (ROE) is -1.09% and return on capital (ROIC) is -88.31%.
| Return on Equity (ROE) | -1.09% |
| Return on Assets (ROA) | -0.37% |
| Return on Capital (ROIC) | -88.31% |
| Revenue Per Employee | $34,953.49 |
| Profits Per Employee | $-646,069.77 |
| Employee Count | 43 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -7.67% in the last 52 weeks. The beta is 0.9, so OncoCyte's price volatility has been higher than the market average.
| Beta | 0.9 |
| 52-Week Price Change | -7.67% |
| 50-Day Moving Average | 2.28 |
| 200-Day Moving Average | 2.77 |
| Relative Strength Index (RSI) | 65.63 |
| Average Volume (20 Days) | 87.7K |
Income Statement
In the last 12 months, OncoCyte had revenue of 1.5M and earned -27.78M in profits. Earnings per share was -3.75.
| Revenue | 1.5M |
| Gross Profit | 413K |
| Operating Income | -25.14M |
| Net Income | -27.78M |
| EBITDA | -23.12M |
| EBIT | -25.14M |
| Earnings Per Share (EPS) | -3.75 |
Balance Sheet
The company has 9.43M in cash and 2.87M in debt, giving a net cash position of 6.56M.
| Cash & Cash Equivalents | 9.43M |
| Total Debt | 2.87M |
| Net Cash | 6.56M |
| Retained Earnings | -289.88M |
| Total Assets | 70.22M |
| Working Capital | -4.3M |
Cash Flow
In the last 12 months, operating cash flow was -23.32M and capital expenditures -281K, giving a free cash flow of -23.61M.
| Operating Cash Flow | -23.32M |
| Capital Expenditures | -281K |
| Free Cash Flow | -23.61M |
| FCF Per Share | -3.09 |
Margins
Gross margin is 27.48%, with operating and profit margins of -1.67K% and -1.85K%.
| Gross Margin | 27.48% |
| Operating Margin | -1.67K% |
| Pretax Margin | -1.65K% |
| Profit Margin | -1.85K% |
| EBITDA Margin | -1.54K% |
| EBIT Margin | -1.67K% |
| FCF Margin | -1.57K% |
Dividends & Yields
OCX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -135.38% |
| FCF Yield | -40.46% |
Analyst Forecast
The average price target for OCX is $4.25, which is 53.4% higher than the current price. The consensus rating is "Hold".
| Price Target | $4.25 |
| Price Target Difference | 53.4% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Jul 25, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | Jul 25, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -7.34 |
| Piotroski F-Score | 2 |